DexCom Inc (DXCM)vsElectrocore LLC (ECOR)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
ECOR
Electrocore LLC
$9.62
+4.68%
HEALTHCARE · Cap: $81.59M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 13343% more annual revenue ($4.97B vs $36.97M). DXCM leads profitability with a 20.1% profit margin vs -40.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
ECOR
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
+82.8%
Fair Value
$31.76
Current Price
$9.62
$22.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Conservative balance sheet, low leverage
Revenue surging 28.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -478.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : ECOR
The strongest argument for ECOR centers on Debt/Equity, Revenue Growth. Revenue growth of 28.0% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : ECOR
The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while ECOR is a growth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
ECOR is growing revenue faster at 28.0% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 24/100), backed by strong 20.1% margins and 13.1% revenue growth. ECOR offers better value entry with a 82.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Electrocore LLC
HEALTHCARE · MEDICAL DEVICES · USA
electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?